Outcome in the real-world of coronary high-risk intervention with drug-eluting stents (ORCHID)—A single-center study comparing Cypher™ sirolimus-eluting with Taxus™ paclitaxel-eluting stents

2006 ◽  
Vol 68 (5) ◽  
pp. 663-668 ◽  
Author(s):  
S. Kumar ◽  
V. Suresh ◽  
B.D. Prendergast ◽  
N.H. Brooks ◽  
P. Wicks ◽  
...  
Keyword(s):  
High Risk ◽  
Real World ◽  
Drug Eluting Stents ◽  
Single Center ◽  
The Real ◽  
Single Center Study ◽  
Drug Eluting ◽  
Center Study

scholarly journals Six-Month Outcomes in Postapproval HeartMate3 Patients: A Single-Center US Experience

2021 ◽  
Author(s):  
Aditya Bansal ◽  
Faisal Akhtar ◽  
Sapna Desai ◽  
Cruz Velasco-Gonzalez ◽  
Anirudh Bansal ◽  
...  
Keyword(s):  
Adverse Events ◽  
Real World ◽  
Limb Ischemia ◽  
Acute Limb Ischemia ◽  
Trial Group ◽  
Single Center ◽  
The Real ◽  
Bridge To Transplant ◽  
Single Center Study ◽  
Center Study

Background The European CE Mark approval study and the MOMENTUM 3 trial demonstrated safety and a reduction in hemocompatibility-related adverse events with use of HeartMate 3 (HM3) device. This single center study investigated the real-world experience in HM3 patients since FDA approval. Methods This retrospective, observational study included patients implanted with the HM3 LVAD as a primary implant between October 2017-March 2020. Patients were divided into trial group and postapproval group. Primary endpoint was survival at 6 months. Secondary endpoints were adverse events including pump thrombosis (requiring pump exchange), stroke, renal failure, acute limb ischemia, re-exploratory for bleeding, gastrointestinal bleeding, right ventricular failure, and driveline infection. Results A total of 189 patients were implanted with HM3 device during the study period. 174 patients met the inclusion criteria: 82 patients in the trial group and 92 patients in the postapproval group. The postapproval group had younger patients, higher pre-operative mean international normalized ratio, and greater numbers of patients with bridge to transplant (BTT) indications, IINTERMACS profile 1, and use of mechanical assist devices (other than IABP) than the trial group. Other characteristics between the two groups were comparable. Overall survival at 6 months in the postapproval group was 93.3% vs. 93.8% ( p=0.88). The postapproval group demonstrated a statistically significant lower incidence of re-explorative surgery for bleeding (10.9% vs 46.3,  p=0.01) than the trial group. Conclusion In this single-center study, the real-world 6-month survival in the postapproval group was comparable to the trial results. Further studies are needed to monitor long-term outcomes.

scholarly journals Conventional single-chamber pacemakers versus transcatheter pacing systems in a “real world” cohort of patients: A comparative prospective single-center study

2021 ◽  
Author(s):  
Jose Luis Martinez-Sande ◽  
Javier Garcia-Seara ◽  
Laila Gonzalez-Melchor ◽  
Moises Rodriguez-Mañero ◽  
Aurora Baluja ◽  
...  
Keyword(s):  
Real World ◽  
Single Center ◽  
Single Chamber ◽  
Single Center Study ◽  
Center Study

Efficacy and Safety of Sesame Oral Immunotherapy—A Real-World, Single-Center Study

2019 ◽  
Vol 7 (8) ◽  
pp. 2775-2781.e2 ◽  
Author(s):  
Liat Nachshon ◽  
Michael R. Goldberg ◽  
Michael B. Levy ◽  
Michael Y. Appel ◽  
Naama Epstein-Rigbi ◽  
...  
Keyword(s):  
Real World ◽  
Oral Immunotherapy ◽  
Efficacy And Safety ◽  
Single Center ◽  
Single Center Study ◽  
Center Study
Sign in / Sign up

Export Citation Format

Share Document